Evidence map›Paper›PMID 38698957›Full record

ArticleActa naturae

Broadly Reactive Nanobody Targeting the H3 Hemagglutinin of the Influenza A Virus.

D V Shcheblyakov, D V Voronina, I A Favorskaya, I B Esmagambetov, I A Alekseeva, A I Korobkova, E I Ryabova, A A Derkaev, V Yu Kan, A Sh Dzharullaeva and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta naturae. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

D V ShcheblyakovNational Research Center for Epidemiology and Microbiology named after the honorary academician N. F. Gamaleya, Moscow, 123098 Russian Federation.
D V VoroninaNational Research Center for Epidemiology and Microbiology named after the honorary academician N. F. Gamaleya, Moscow, 123098 Russian Federation.
I A FavorskayaNational Research Center for Epidemiology and Microbiology named after the honorary academician N. F. Gamaleya, Moscow, 123098 Russian Federation.
I B EsmagambetovNational Research Center for Epidemiology and Microbiology named after the honorary academician N. F. Gamaleya, Moscow, 123098 Russian Federation.
I A AlekseevaNational Research Center for Epidemiology and Microbiology named after the honorary academician N. F. Gamaleya, Moscow, 123098 Russian Federation.
A I KorobkovaNational Research Center for Epidemiology and Microbiology named after the honorary academician N. F. Gamaleya, Moscow, 123098 Russian Federation.
E I RyabovaNational Research Center for Epidemiology and Microbiology named after the honorary academician N. F. Gamaleya, Moscow, 123098 Russian Federation.
A A DerkaevNational Research Center for Epidemiology and Microbiology named after the honorary academician N. F. Gamaleya, Moscow, 123098 Russian Federation.
V Yu KanNational Research Center for Epidemiology and Microbiology named after the honorary academician N. F. Gamaleya, Moscow, 123098 Russian Federation.
A Sh DzharullaevaNational Research Center for Epidemiology and Microbiology named after the honorary academician N. F. Gamaleya, Moscow, 123098 Russian Federation.
A I TukhvatulinNational Research Center for Epidemiology and Microbiology named after the honorary academician N. F. Gamaleya, Moscow, 123098 Russian Federation.
A S BandelyukNational Research Center for Epidemiology and Microbiology named after the honorary academician N. F. Gamaleya, Moscow, 123098 Russian Federation.
M M ShmarovNational Research Center for Epidemiology and Microbiology named after the honorary academician N. F. Gamaleya, Moscow, 123098 Russian Federation.
D Yu LogunovNational Research Center for Epidemiology and Microbiology named after the honorary academician N. F. Gamaleya, Moscow, 123098 Russian Federation.
A L GintsburgNational Research Center for Epidemiology and Microbiology named after the honorary academician N. F. Gamaleya, Moscow, 123098 Russian Federation.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monoclonal antibodies and recombinant antibody fragments are a very promising therapeutic tool to combat infectious diseases. Due to their unique paratope structure, nanobodies (VHHs) hold several advantages over conventional monoclonal antibodies, especially in relation to viral infections. Influenza A viruses (IAVs) remain a major threat to public health. The hemagglutinin (HA) protein is the main protective and immunodominant antigen of IAVs. In this study, three broadly reactive nanobodies (D9.2, E12.2, and D4.2) to H3N2 influenza strains were isolated and Fc-fusion proteins (VHH-Fcs) were obtained and characterized

Indexed as

Fc regionhemagglutinininfluenza virusnanobodysingle-domain antibody

Identifiers

PMID38698957
PMCPMC11062109

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.